Figure 1From: Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation Overall Survival in relation to response to fotemustine (all patients, n = 40). Responders = patients achieving partial response – Non-responders = patients achieving either stable or progressive disease.Back to article page